FDA Issues Warning For SGLT2 Inhibitors

The U.S. Food and Drug Administration (FDA) issued a warning concerning sodium-glucose cotransporter-2 (SGLT2) inhibitors—such as canagliflozin, dapagliflozin and empagliflozin—stating that these type 2 diabetes drugs may lead to ketoacidosis. The agency notes that they will continue to investigate the safety of these drugs and urges patients to remain alert for signs of ketoacidosis, such as difficulty breathing, nausea, vomiting, abdominal pain, confusion and unusual fatigue.

Read more in the FDA’s announcement.


< Back to Listings